These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12543658)

  • 1. Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol.
    Walsh S; Shah A; Mond J
    Antimicrob Agents Chemother; 2003 Feb; 47(2):554-8. PubMed ID: 12543658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysostaphin in treatment of neonatal Staphylococcus aureus infection.
    Oluola O; Kong L; Fein M; Weisman LE
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2198-200. PubMed ID: 17420212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Site-specific PEGylation of recombinant lysostaphin].
    Lu H; Zhangi Y; Huang Q
    Sheng Wu Gong Cheng Xue Bao; 2016 Jan; 32(1):127-34. PubMed ID: 27363205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended nasal residence time of lysostaphin and an anti-staphylococcal monoclonal antibody by delivery in semisolid or polymeric carriers.
    Walsh S; Kokai-Kun J; Shah A; Mond J
    Pharm Res; 2004 Oct; 21(10):1770-5. PubMed ID: 15553221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion of Lysostaphin to an Albumin Binding Domain Prolongs Its Half-Life and Bactericidal Activity in the Systemic Circulation.
    Grishin AV; Shestak NV; Lavrova NV; Lyashchuk AM; Popova LI; Strukova NV; Generalova MS; Ryazanova AV; Polyakov NB; Galushkina ZM; Soboleva LA; Boksha IS; Karyagina AS; Lunin VG
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31395814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Site-directed mutagenesis and sulfhydryl PEGylation of lysostaphin].
    Wu H; Fang W; Yuan J; Peng H; Zhang X; Wang Y; Xiao Y
    Sheng Wu Gong Cheng Xue Bao; 2011 Nov; 27(11):1623-30. PubMed ID: 22393717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37.
    Sadeghi S; Bakhshandeh H; Ahangari Cohan R; Peirovi A; Ehsani P; Norouzian D
    Int J Nanomedicine; 2019; 14():9777-9792. PubMed ID: 31849468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-directed targeting of lysostaphin adsorbed onto polylactide nanoparticles increases its antimicrobial activity against S. aureus in vitro.
    Satishkumar R; Vertegel AA
    Nanotechnology; 2011 Dec; 22(50):505103. PubMed ID: 22107797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
    Placencia FX; Kong L; Weisman LE
    Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic.
    Oldham ER; Daley MJ
    J Dairy Sci; 1991 Dec; 74(12):4175-82. PubMed ID: 1787188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
    Climo MW; Patron RL; Goldstein BP; Archer GL
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1355-60. PubMed ID: 9624475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.
    Wu JA; Kusuma C; Mond JJ; Kokai-Kun JF
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3407-14. PubMed ID: 14576095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of lysostaphin in HeLa cells protects from host cell killing by intracellular Staphylococcus aureus.
    Klein M; Krönke M; Krut O
    Med Microbiol Immunol; 2006 Sep; 195(3):159-63. PubMed ID: 16482441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model.
    Kokai-Kun JF; Chanturiya T; Mond JJ
    J Antimicrob Chemother; 2007 Nov; 60(5):1051-9. PubMed ID: 17848374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysostaphin: an antistaphylococcal agent.
    Kumar JK
    Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient adsorption of lysostaphin on bacterial cells of lysostaphin-resistant Staphylococcus aureus mutant.
    Sakurada J; Murai M; Zhijun L; Usui A; Seki K; Kobayashi K; Sumi Y; Jitsukawa H; Masuda S
    Microbiol Immunol; 1993; 37(1):29-34. PubMed ID: 8474355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China.
    Yang XY; Li CR; Lou RH; Wang YM; Zhang WX; Chen HZ; Huang QS; Han YX; Jiang JD; You XF
    J Med Microbiol; 2007 Jan; 56(Pt 1):71-76. PubMed ID: 17172520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Influence of Dimerization on the Pharmacokinetics and Activity of an Antibacterial Enzyme Lysostaphin.
    Grishin AV; Lavrova NV; Lyashchuk AM; Strukova NV; Generalova MS; Ryazanova AV; Shestak NV; Boksha IS; Polyakov NB; Galushkina ZM; Soboleva LA; Vetchinin SS; Pavlov VM; Karyagina AS; Lunin VG
    Molecules; 2019 May; 24(10):. PubMed ID: 31100806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
    Graham S; Coote PJ
    J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unprotonated Short-Chain Alkylamines Inhibit Staphylolytic Activity of Lysostaphin in a Wall Teichoic Acid-Dependent Manner.
    Wu X; Kwon SJ; Kim D; Zha J; Mora-Pale M; Dordick JS
    Appl Environ Microbiol; 2018 Jul; 84(14):. PubMed ID: 29728390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.